Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.
de Wild SR, de Munck L, Simons JM, Verloop J, van Dalen T, Elkhuizen PHM, Houben RMA, van Leeuwen AE, Linn SC, Pijnappel RM, Poortmans PMP, Strobbe LJA, Wesseling J, Voogd AC, Boersma LJ. de Wild SR, et al. Among authors: houben rma. Lancet Oncol. 2022 Sep;23(9):1201-1210. doi: 10.1016/S1470-2045(22)00482-X. Epub 2022 Aug 8. Lancet Oncol. 2022. PMID: 35952707
Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients.
van Baardwijk A, Bosmans G, Dekker A, van Kroonenburgh M, Boersma L, Wanders S, Ollers M, Houben R, Minken A, Lambin P, De Ruysscher D. van Baardwijk A, et al. Radiother Oncol. 2007 Feb;82(2):145-52. doi: 10.1016/j.radonc.2007.01.007. Epub 2007 Jan 26. Radiother Oncol. 2007. PMID: 17258339
PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes.
van Baardwijk A, Bosmans G, Boersma L, Buijsen J, Wanders S, Hochstenbag M, van Suylen RJ, Dekker A, Dehing-Oberije C, Houben R, Bentzen SM, van Kroonenburgh M, Lambin P, De Ruysscher D. van Baardwijk A, et al. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):771-8. doi: 10.1016/j.ijrobp.2006.12.067. Epub 2007 Mar 29. Int J Radiat Oncol Biol Phys. 2007. PMID: 17398018
Customized computed tomography-based boost volumes in breast-conserving therapy: use of three-dimensional histologic information for clinical target volume margins.
Hanbeukers B, Borger J, van den Ende P, van der Ent F, Houben R, Jager J, Keymeulen K, Murrer L, Sastrowijoto S, van de Vijver K, Boersma L. Hanbeukers B, et al. Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):757-63. doi: 10.1016/j.ijrobp.2008.11.048. Epub 2009 Mar 21. Int J Radiat Oncol Biol Phys. 2009. PMID: 19304402
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.
Aerts HJ, van Baardwijk AA, Petit SF, Offermann C, Loon Jv, Houben R, Dingemans AM, Wanders R, Boersma L, Borger J, Bootsma G, Geraedts W, Pitz C, Simons J, Wouters BG, Oellers M, Lambin P, Bosmans G, Dekker AL, De Ruysscher D. Aerts HJ, et al. Radiother Oncol. 2009 Jun;91(3):386-92. doi: 10.1016/j.radonc.2009.03.006. Epub 2009 Mar 28. Radiother Oncol. 2009. PMID: 19329207 Free PMC article.
Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating study.
De Ruysscher D, Dehing C, Bentzen SM, Houben R, Dekker A, Wanders R, Borger J, Hochstenbag M, Boersma L, Geskes G, Dingemans AM, Bootsma G, Lammering G, Lambin P. De Ruysscher D, et al. Radiother Oncol. 2009 Dec;93(3):389-95. doi: 10.1016/j.radonc.2009.06.004. Epub 2009 Jul 1. Radiother Oncol. 2009. PMID: 19576645 Review.
89 results